Taking a quick snapshot of our pipeline, you can see NUEDEXTA on the top there with FDA approval for the treatment of pseudobulbar affect. In addition, you can see NUEDEXTA or AVP-923 in Phase II studies for central neuropathic pain in multiple sclerosis. In regards to behavioral disturbances in Alzheimer’s, we’re currently working on our investigation on New Drug Application. We’re planning on filing that with the FDA in the second quarter of this year with the intent of enrolling our first patient in mid-to-late summer of this year. And, finally, our diabetic peripheral neuropathic pain, you may be aware that we announced a publication of our Phase III studies in diabetic peripheral neuropathic pain a number of weeks ago, that program looks very promising. However, we it on hold right now until we get the results of our neuropathic pain and multiple sclerosis. Additionally on the slide, you now see the addition of our deuterated dextromethorphan program. That is a preclinical asset that’s what we’ve planned on to moving that into the clinic as quickly as possible. And then, finally, our non-CNS related products ABREVA and Thravixa.So a quick overview of the deal that we signed with Concert Pharmaceuticals this morning, it is an exclusive worldwide license agreement to develop and commercialize deuterated dextromethorphan. Concert is a privately-held company in Lexington, Massachusetts. We’re getting a several deuterated dextromethorphan compounds. And what’s very exciting for us is that deuterated dextromethorphan is a new chemical entity and therefore has the associated intellectual property with the new chemical entity and the existing patents lasts through 2030, with opportunities for extension, as well as additional patent applications in the future. And I’ll go into a little more detail on the deuterated technology later in the presentation.
Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.